SMI completes development of SkinSpect for early detection of melanoma

SMI completes development of SkinSpect for early detection of melanoma

News and Articles
Oct 7 2010

Cascade Technologies Corp. (OTCBB: CSDT) announced today that its wholly-owned subsidiary, Spectral Molecular Imaging, Inc. (SMI), completed, under a previously introduced accelerated timeline, the development of its initial product SkinSpect™, aimed at early detection of melanoma by the company’s proprietary form of hyperspectral imaging. The new instrument was unveiled on September 29 at SMI’s corporate headquarters in Beverly Hills, to a group of colleagues, medical professionals and device experts and other interested persons. “SkinSpect™,” according to Dr. Erik Lindsley, President of SMI, “incorporates advances in hyperspectral imaging, autofluorescence measurement and polarization-gated detection achieved by SMI researchers and consultants through experiences cumulatively reaching more than 100 years. The software controlling image acquisition and handling is completely new, driven by an intuitive touch screen interface and allowing effortless data and patient monitoring, image archiving and analysis, and internet-based data transfer and tele-consults; its design is compliant with and conducive to electronic medical record generation and tracking.”

“is extremely versatile in acquiring high-resolution image data non-invasively from suspicious skin lesions, on the surface and under it, with a speed that minimizes motion artifacts.”

“The new system,” noted Dr. Daniel Farkas, Chairman and Chief Executive Officer, “is extremely versatile in acquiring high-resolution image data non-invasively from suspicious skin lesions, on the surface and under it, with a speed that minimizes motion artifacts.” “Moreover,” added Dr. Farkas, “we have diligently applied the great potential of hyperspectral imaging in detecting disease with high sensitivity and specificity in the past but nothing seems more exciting to us than the prospect of deploying this technology – upon regulatory approval – for finding early melanoma and thus materially increasing likelihoods of saving lives and reducing treatment costs — clearly unmet needs today.”

Source:

Cascade Technologies Corp.

Source: www.news-medical.net

Rate article
Add a comment